Deciphering neuronal deficit and protein profile changes in human brain organoids from patients with creatine transporter deficiency

Creatine transporter deficiency (CTD) is an X-linked disease caused by mutations in the SLC6A8 gene. The impaired creatine uptake in the brain results in intellectual disability, behavioral disorders, language delay, and seizures. In this work, we generated human brain organoids from induced pluripotent stem cells of healthy subjects and CTD patients. Brain organoids from CTD donors had reduced creatine uptake compared with those from healthy donors. The expression of neural progenitor cell markers SOX2 and PAX6 was reduced in CTD derived organoids, while GSK3β, a key regulator of neurogenesis, was up-regulated. Shotgun proteomics combined with integrative bioinformatic and statistical analysis identified changes in abundance of proteins associated with intellectual disability, epilepsy, and autism. Re-establishment of the expression a functional SLC6A8 in CTD-derived organoids restored creatine uptake and normalized the expression of SOX2, GSK3β and other key proteins associated with clinical features of CTD patients. Our brain organoid model opens new avenues for further characterizing the CTD pathophysiology and supports the concept that reinstating creatine levels in patients with CTD could result in therapeutic efficacy. Summary Heading: Therapeutic targets associated with Creatine Transporter Deficiency

[1]  O. Braissant,et al.  Current and potential new treatment strategies for creatine deficiency syndromes. , 2021, Molecular genetics and metabolism.

[2]  C. Sandi,et al.  Creatine transporter–deficient rat model shows motor dysfunction, cerebellar alterations, and muscle creatine deficiency without muscle atrophy , 2021, bioRxiv.

[3]  H. H. Zhang,et al.  Creatine transporter deficiency impairs stress adaptation and brain energetics homeostasis , 2021, JCI insight.

[4]  Mingyan Lin,et al.  DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome , 2021, Journal of Clinical Investigation.

[5]  H. Harati,et al.  Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes , 2021, Molecular Biology Reports.

[6]  H. Eldar-Finkelman,et al.  Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration , 2021, Cells.

[7]  R. Hamoudi,et al.  M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome , 2020, Frontiers in Immunology.

[8]  M. Freissmuth,et al.  The Creatine Transporter Unfolded: A Knotty Premise in the Cerebral Creatine Deficiency Syndrome , 2020, Frontiers in Synaptic Neuroscience.

[9]  A. Becchetti,et al.  An early Sox2-dependent gene expression programme required for hippocampal dentate gyrus development , 2020, bioRxiv.

[10]  Stephen J. Bruce,et al.  A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism , 2020, Scientific Reports.

[11]  D. Biard,et al.  Long Term Gene Expression in Human Induced Pluripotent Stem Cells and Cerebral Organoids to Model a Neurodegenerative Disease , 2020, Frontiers in Cellular Neuroscience.

[12]  Y. Hérault,et al.  A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment , 2020, Scientific Reports.

[13]  O. Langer,et al.  Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model , 2019, Scientific Reports.

[14]  B. Alpha-Bazin,et al.  Evaluation of Sample Preparation Methods for Fast Proteotyping of Microorganisms by Tandem Mass Spectrometry , 2019, Front. Microbiol..

[15]  Marla K. Perna,et al.  Deletion of the creatine transporter gene in neonatal, but not adult, mice leads to cognitive deficits , 2019, Journal of inherited metabolic disease.

[16]  J. Benoit,et al.  Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency. , 2019, Nanomedicine.

[17]  J. Mikol,et al.  Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes , 2018, PloS one.

[18]  R. Hevner,et al.  GSK3β Inhibition Restores Impaired Neurogenesis in Preterm Neonates With Intraventricular Hemorrhage. , 2018, Cerebral cortex.

[19]  K. Õunap,et al.  Treatment outcome of creatine transporter deficiency: international retrospective cohort study , 2018, Metabolic Brain Disease.

[20]  Maria K. Jaakkola,et al.  ROTS: An R package for reproducibility-optimized statistical testing , 2017, PLoS Comput. Biol..

[21]  T. Wieland,et al.  De novo microdeletions and point mutations affecting SOX2 in three individuals with intellectual disability but without major eye malformations , 2017, American journal of medical genetics. Part A.

[22]  J. Armengaud,et al.  RNA-binding proteins are a major target of silica nanoparticles in cell extracts , 2016, Nanotoxicology.

[23]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[24]  J. Ávila,et al.  GSK3β Overexpression in Dentate Gyrus Neural Precursor Cells Expands the Progenitor Pool and Enhances Memory Skills* , 2016, The Journal of Biological Chemistry.

[25]  David J. Price,et al.  Regulation of cerebral cortical neurogenesis by the Pax6 transcription factor , 2015, Front. Cell. Neurosci..

[26]  G. Cioni,et al.  A novel mouse model of creatine transporter deficiency , 2014, F1000Research.

[27]  Madeline A. Lancaster,et al.  Generation of cerebral organoids from human pluripotent stem cells , 2014, Nature Protocols.

[28]  G. Mancini,et al.  X-linked creatine transporter deficiency: clinical aspects and pathophysiology , 2014, Journal of Inherited Metabolic Disease.

[29]  J. Armengaud,et al.  Proteogenomic insights into salt tolerance by a halotolerant alpha-proteobacterium isolated from an Andean saline spring. , 2014, Journal of proteomics.

[30]  Madeline A. Lancaster,et al.  Cerebral organoids model human brain development and microcephaly , 2013, Nature.

[31]  Chun-Teng Huang,et al.  SOX2–LIN28/let-7 pathway regulates proliferation and neurogenesis in neural precursors , 2013, Proceedings of the National Academy of Sciences.

[32]  P. de Lonlay,et al.  Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency. , 2013, Journal of medicinal chemistry.

[33]  E. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[34]  A. Munnich,et al.  Functional and electrophysiological characterization of four non-truncating mutations responsible for creatine transporter (SLC6A8) deficiency syndrome , 2013, Journal of Inherited Metabolic Disease.

[35]  Jesús Avila,et al.  GSK3 and tau: two convergence points in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[36]  E. Tortosa,et al.  Microtubule-associated Protein 1B (MAP1B) Is Required for Dendritic Spine Development and Synaptic Maturation , 2011, The Journal of Biological Chemistry.

[37]  Joseph F. Clark,et al.  Creatine Transporter (CrT; Slc6a8) Knockout Mice as a Model of Human CrT Deficiency , 2011, PloS one.

[38]  K. Maclennan,et al.  Differential expression of NF-κB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism , 2010, Leukemia.

[39]  Eun-Mi Hur,et al.  GSK3 signalling in neural development , 2010, Nature Reviews Neuroscience.

[40]  B. Doble,et al.  GSK-3 is a master regulator of neural progenitor homeostasis , 2009, Nature Neuroscience.

[41]  Boris Jerchow,et al.  Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates , 2009, Nature Genetics.

[42]  Piotr Fryzlewicz,et al.  Data and text mining Variance stabilization and normalization for one-color microarray data using a data-driven multiscale approach , 2006 .

[43]  Charles E. Schwartz,et al.  X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology , 2006, Human Genetics.

[44]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Schwartz,et al.  X-linked creatine transporter defect: An overview , 2003, Journal of Inherited Metabolic Disease.

[46]  W. Ball,et al.  The clinical syndrome of creatine transporter deficiency , 2003, Molecular and Cellular Biochemistry.

[47]  Masahiko Watanabe,et al.  The Blood–Brain Barrier Creatine Transporter is a Major Pathway for Supplying Creatine to the Brain , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  B. Wong,et al.  Irreversible brain creatine deficiency with elevated serum and urine creatine: A creatine transporter defect? , 2001, Annals of neurology.

[49]  J. Benoit,et al.  Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency. , 2015, Nanomedicine.

[50]  S. Stockler,et al.  Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. , 2007, Sub-cellular biochemistry.